The strong non-GAAP EPS beat suggests improving profitability, but the guidance cut signals near-term pressure from the pain portfolio and AG Nucynta pricing. Traders should watch the back-to-school ADHD season for JORNAY PM and AZSTARYS ramp, and monitor pain portfolio trends in Q3 earnings for confirmation of stabilization or further erosion.
Drug in focus
COLL drug pipeline →Nucynta ER
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already on the market — approved since 2008 (IR) and 2011 (ER)
- Next catalyst
- None dated
What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $29.11entry
- T+1 · 3mo ago +1.24%α +0.63% · $29.47
- T+5 · 3mo ago −3.30%α −4.51% · $28.15
- T+20 · 3mo ago −18.58%α −19.18% · $23.70
- T+60 · 18d ago −18.24%α −16.57% · $23.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M (+6% YoY). However, the company lowered full-year 2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M), citing weaker-than-expected authorized generic Nucynta pricing. The GAAP net loss of ($15.1M) reflects acquisition-related costs from the recently closed AZSTARYS deal. The ADHD portfolio (JORNAY PM +41% YoY, AZSTARYS $12.9M partial quarter) is strong, but the pain portfolio declined 9% YoY, creating a mixed outlook.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS $1.92 vs consensus $1.48, beat 29.7%
- Q2 2026 revenue $199.9M, +6% YoY
- GAAP net loss ($15.1M) due to acquisition-related expenses and amortization
- Completed AZSTARYS acquisition in May; added $12.9M in partial quarter revenue
- Lowered FY2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M)
- JORNAY PM net revenue grew 41% YoY to $46.1M; pain portfolio fell 9% to $140.9M
- Cash from operations $71.3M; cash and marketable securities $129.5M at quarter end
Financial Impact
Adjusted EPS beat by $0.44 vs consensus; full-year guidance cut by ~$40M on both product revenue and adjusted EBITDA
Risk Factors
- Continued decline in pain portfolio (Belbuca, Xtampza ER, Nucynta franchise)
- Lower-than-expected AG Nucynta pricing impacting full-year EBITDA
- Integration risk and debt load from the AZSTARYS acquisition (term notes payable $852.8M)
- Potential share dilution from convertible notes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-053849 |
| Document: collq22026earningspresen.htm | 0001628280-26-053849 |
| Document: coll-20260806.htm | 0001628280-26-053849 |
| Document: 0001628280-26-053849-index-headers.html | 0001628280-26-053849 |
| Document: 0001628280-26-053849-index.html | 0001628280-26-053849 |
| Document: 0001628280-26-053849.txt | 0001628280-26-053849 |
| 8-K Data (Synthetic) | 0001628280-26-053849 |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers